LETTERS

Medical marijuana in treating obstructive sleep apnea

The results of the recent pharmacotherapy of apnea by cannabimimetic enhancement (PACE) trial that studied the effects of dronabinol (a cannabinoid) on the effects of obstructive sleep apnea look promising.¹ In light of this study and the upcoming legalization of marijuana in Canada, could the authors of the recent *CMAJ* review² on the diagnosis and treatment of obstructive sleep apnea in adults please comment on the use of marijuana and its pharmacologic derivatives in the treatment of obstructive sleep apnea?

Additionally, modafinil is available by prescription by primary care practitioners for patients with obstructive sleep apnea who report excessive daytime sedation. I am interested in the authors' opinion on its use.

Harold A. Pupko MD

General practitioner (practising in mental health), North York, Ont.

Cite as: CMAJ 2018 May 7;190:E572. doi: 10.1503/cmaj.69128

References

- 1. Carley DW, Prasad B, Reid KJ, et al. Pharmacotherapy of apnea by cannabimimetic enhancement, the PACE clinical trial: effects of dronabinol in obstructive sleep apnea. *Sleep* 2018;41:zsx184. doi:10.1093/sleep/zsx184.
- Laratta CR, Ayas NT, Povitz M, et al. Diagnosis and treatment of obstructive sleep apnea in adults. CMAJ 2017;189:E1481-8.

Competing interests: None declared.